

Press Release



ASKA Animal Health Signs Exclusive Licensing Agreement for the Commercialization of Trilostane Tablets “ASKA” in Taiwan

TOKYO, October 2, 2026 – ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886, Head Office: Minato-ku, Tokyo / President, Representative Director: Sohta Yamaguchi) announced that its subsidiary, ASKA Animal Health Co., Ltd. (Head Office: Minato-ku, Tokyo / President: Fumiyoshi Yamaguchi; hereinafter “ASKA Animal Health”), has entered into an exclusive licensing agreement with a company engaged in the veterinary pharmaceutical business in Taiwan for the commercialization of Trilostane Tablets “ASKA”, a treatment for canine hyperadrenocorticism (Cushing’s syndrome), in Taiwan.

Under this agreement, the parties will proceed with the necessary procedures to obtain marketing approval in Taiwan. Following the submission of a marketing authorization application to the Taiwanese regulatory authorities by the local commercialization partner, sales of the product are planned to commence after approval is granted.

Trilostane Tablets “ASKA” is a veterinary pharmaceutical product indicated for the treatment of canine hyperadrenocorticism (Cushing’s syndrome). The product lineup includes low-strength tablets suitable for small dogs. In addition, the tablets are film-coated to provide a formulation design that is easier and safer for both dogs and their owners to handle. Through the introduction of this product to the Taiwanese market, ASKA Animal Health aims to contribute to the advancement of veterinary medicine and the maintenance of companion animal health in Taiwan.

This agreement represents ASKA Animal Health’s first full-scale overseas business initiative and is positioned as an important step in the expansion of the ASKA Group’s international business. In the animal health business, the Group is strengthening its domestic foundation while actively pursuing overseas opportunities, particularly in Asia, and regards this project as the first step in that effort. Leveraging the Group’s strengths, the ASKA Group will continue to expand its products and services globally, create new business opportunities, and enhance corporate value.

Product Overview

Item	Description
Product Name	Trilostane Tablets “ASKA”
Indication	Canine hyperadrenocorticism (Cushing’s syndrome)
Active Ingredient	Trilostane
Description	Trilostane is an active pharmaceutical ingredient used in the treatment of canine hyperadrenocorticism (Cushing’s syndrome) by suppressing the excessive production of adrenal corticosteroid hormones.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Group Management Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp